Delta variant doubles COVID hospitalization risk: research | Coronavirus pandemic news

Research published in The Lancet shows that the protection of the vaccine against the Delta variant first discovered in India may be lower than the protection against the Alpha variant first discovered in the UK.

The Delta coronavirus variant has doubled the risk of hospitalization compared to the previous variant that dominated the UK, but two doses of the vaccine still provide strong protection. A Scot Learn found it.

According to the study, early evidence suggests that a vaccine against the Delta variant first discovered in India may be less protective than the Alpha variant first discovered in Kent, southeast England.

British Prime Minister Boris Johnson is expected to postpone the end of England’s restrictions on COVID-19 on Monday because of the rapid increase in cases of the Delta variant, which is also more likely to spread than the Alpha variant.

In a research letter published on Monday in The Lancet, the study looked at 19,543 community cases and 377 hospitalized cases among the 5.4 million people in Scotland, of which 7,723 cases and 1,234 hospitalized cases were found to have Delta variant.

Chris Robertson, professor of public health epidemiology at Strathclyde University, said that after adjusting for age and comorbidities, the Delta variant roughly doubled the risk of hospital admission, but the vaccine still reduced this risk.

He told reporters: “If your test result is positive, then get two doses of vaccine or one dose of vaccine for 28 days, and your risk of hospital admission will be reduced by approximately 70%.”

The British Foreign Secretary stated that the government hopes to use the extra time to give millions of young people a double blow before it is completely reopened. [File: Shawn Rocco/Duke Health/Handout/Reuters]

Two weeks after the second dose, Pfizer’s BioNTech vaccine was found to have 79% protection against Delta variant infections and 92% protection against Alpha variants.

The Oxford-AstraZeneca vaccine has a protection rate of 60% for Delta and 73% for Alpha.

“The Oxford-AstraZeneca vaccine does not seem to be as effective as the Pfizer-BioNTech vaccine in preventing SARS-CoV-2 infection,” the author wrote in the Lancet article.

However, they added: “Given the observational nature of these data, estimates of vaccine effectiveness need to be interpreted with caution.”

Relax lock

Scientists say that two doses of the vaccine are much better than one dose of vaccine for the protection of Delta variants. The delay in relaxation of the blockade in the UK will help more people receive the second dose of the vaccine and enhance their immune response.

Aziz Sheikh, director of the Arthur Institute at the University of Edinburgh, said: “I think that any form of window of opportunity increase will help before the lockdown is completely over.”

Foreign Secretary Dominic Raab (Dominic Raab) said over the weekend that the government hopes to use the extra time to give millions of young people a double blow.

He said that while the vaccine weakened the link between infection and hospitalization, they wanted to ensure that it was “cut and destroyed.”

He said that cautious approach is necessary to ensure that unlocking is “irreversible” and that they do not have to “step in and out of measures.”

The latest daily government data on Monday showed that there were 7,742 new laboratory confirmed cases in the UK, and the number of infections rose again.

Source link

Recommended For You

About the Author: Agnes Zang